An International, Multicentre, Open-label Study To Evaluate The Efficacy and Safety of Two Different Vaccination Regimens of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia That Are In Remission With Persistent MRD
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Vididencel (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Acronyms ADVANCE II
- Sponsors Mendus
- 17 Jun 2024 Results presented in a Mendus Media Release.
- 17 Jun 2024 According to a Mendus media release, data from this study presented at the annual European Hematology Association conference (EHA).
- 14 Feb 2024 According to a Mendus media release, based on the ADVANCE II data and data from the first stage of the CADENCE trial, Mendus expects to be in a position to engage in a global registration path for vididencel in 2025.